About Abwiz Bio & Our Recombinant Antibody Production
We provide researchers worldwide with top-quality monoclonal antibodies
through novel immunization and unique cloning methods using phage display technology.
We will produce antibodies and develop technologies with creative minds to contribute to basic and applied research, diagnostics, and therapeutics for the betterment of healthcare.
Scientists at Abwiz Bio are experts in the field of antibody discovery, phage display technology, and recombinant antibody production.
Libraries at Abwiz Bio are made using our state-of-the-art cloning method to maintain maximum
diversity from the immune source (US 9,890,414), and the best antibodies are selected through various strategies for affinity and specificity.
Abwiz Bio is specialized in the discovery of monoclonal antibodies with tailored specificities and affinities.
We not only make our own antibodies, but also seek to collaborate with academia and pharma to speed up the development of useful antibodies and minimize the cost on both ends.
We are Abwiz Bio
Abwiz Bio was founded in September 2012 by two scientists in San Diego to address the quality issues of antibodies currently used in research.
Along with our strong selection strategies, our unique cloning method "RabWiz<sup>TM</sup>" (US 9,890,414) enables us to obtain a wide range of antibodies that could have been missed by hybridoma technology or other phage display methods. Our fully-functional rabbit monoclonal antibodies developed from our "RabWiztm" technology have more diverse recognition of antigen epitopes with higher-specificity and higher-affinity than our competitors, facilitating reliable target detection. We have also developed a mouse recombinant antibody production and development platform using our phage technology.
We provide the highest quality monoclonal antibodies to the research reagent, clinical diagnostics, and therapeutics industries. We develop monoclonal antibodies and license and/or OEM our products to our customers, as well as help customers develop monoclonal antibodies as a contract research organization. Contact us today to see how our recombinant antibody production and development platform can help you achieve your goals.
Founder and COO/CSO
Toshi Maruyama is the Chief Operating Officer (COO) and Chief Scientific Officer (CSO).
As COO/CSO, he is responsible for research, development, and manufacture of products.
Prior to founding Abwiz Bio, he acquired his skills in phage display in the lab of Dennis Burton at The Scripps Research Institute, La Jolla, CA and has held several senior scientist and management roles at Alexion Antibody Technologies, Calmune, and Nitto Denko Technical, USA.
He has over 20 years of antibody development experience in academia and pharma. Toshi obtained his MD and PhD degree at Tokyo Medical and Dental University.
Founder and CEO
CJ Okumura is the Chief Executive Officer (CEO), and is responsible for strategy and directing of the company.
Prior to founding Abwiz Bio, CJ held a senior business development leadership position in BioLegend. He was a post doctoral fellow at Nolan laboratory in Stanford University and Dr Hirohisa Saito laboratory in Riken Research Center for Allergy and Immunology. Expertise in Immunology, molecular biology and business development.
CJ holds MBA at UCSD, RADY School of management, DDS and PhD at Tokyo Dental College.